Advertisement

Prostate Cancer

  • Michael A. Garcia
  • Eric K. Hansen
  • Mack RoachIII
Chapter

Abstract

This chapter will discuss the screening, work-up, diagnosis, and management for prostate cancer.

Keywords

Prostate cancer Screening Gleason score Radiation Prostatectomy Salvage therapy Brachytherapy Androgen deprivation therapy 

Notes

Acknowledgment

We thank Siavash Jabbari MD for his work on the prior edition of this chapter.

References

  1. Abdollah F, Karnes RJ, Suardi N, et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J Clin Oncol. 2014;32(35):3939–47.PubMedGoogle Scholar
  2. Al-Mamgani A, van Putten WL, Heemsbergen WD, et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;72(4):980–8.PubMedGoogle Scholar
  3. Aluwini S, Pos F, Schimmel E, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2016;17(4):464–74.PubMedGoogle Scholar
  4. American Cancer Society recommendations for prostate cancer early detection: http://www.cancer.org/cancer/prostatecancer/moreinformation/prostatecancerearlydetection/prostate-cancer-early-detection-acs-recommendations. Accessed 9 Aug 2016.
  5. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR. AJCC cancer staging manual. 8th ed: Springer; 2017.Google Scholar
  6. Andriole GL, Crawford ED, Grubb RL, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–32.PubMedPubMedCentralGoogle Scholar
  7. Arcangeli S, Strigari L, Gomellini S, et al. Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1172–8.PubMedGoogle Scholar
  8. Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–63.PubMedGoogle Scholar
  9. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932–42.PubMedPubMedCentralGoogle Scholar
  10. Bittner HJ, Orio PF, Merrick GS, et al. The American College of Radiology and the American Brachytherapy Society practice parameter for transperineal permanent brachytherapy of prostate cancer. Brachytherapy. 2017;16:59–67.PubMedGoogle Scholar
  11. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. NEJM. 2009;360:2516–27.PubMedGoogle Scholar
  12. Bolla M, van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–73.PubMedGoogle Scholar
  13. Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380(9858):2018–27.PubMedGoogle Scholar
  14. Bolla M, Maingon P, Carrie C, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. JCO. 2016;34(15):1748–56.Google Scholar
  15. Bul M, van den Bergh RCN, Zhu X, et al. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. BJU Int. 2012;110(11):1672–7.PubMedGoogle Scholar
  16. Carrie C, Hasbini A, de Laroche G, et al. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2016;17(6):747–56.PubMedGoogle Scholar
  17. Catton CN, Lukka H, Julian JA, et al. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. ASCO Meeting Abstracts. 2016;34 (suppl; abstr 5003).Google Scholar
  18. Chun FK, Briganti A, Shariat SF, et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU Int. 2006;98(2):329–34.PubMedGoogle Scholar
  19. Connolly JA, Shinohara K, Presti JC, Carroll PR. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology. 1996;47(2):225–31.PubMedGoogle Scholar
  20. Cooperberg MR, Pasta DJ, Elkin EP, et al. The University of California, San Francisco cancer of the prostate risk assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173(6):1938–42.PubMedPubMedCentralGoogle Scholar
  21. D’Amico AV, Chen M-H, Renshaw A, Loffredo M, Kantoff PW. Long-term follow-up of a randomized trial of radiation with or without androgen deprivation therapy for localized prostate cancer. JAMA. 2015;314(12):1291–3. https://doi.org/10.1001/jama.2015.8577.PubMedGoogle Scholar
  22. D’Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440–7.PubMedGoogle Scholar
  23. Davis BJ, Horwitz EM, Lee WR, et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012;11(1):6–19.Google Scholar
  24. Davis EJ, Beebe-Dimmer JL, Yee CL, Cooney KA. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer. 2014;120(17):2735–41.PubMedPubMedCentralGoogle Scholar
  25. Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2014;15(4):464–73.PubMedGoogle Scholar
  26. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60.PubMedPubMedCentralGoogle Scholar
  27. Den RB, Yousefi K, Trabulsi EJ, et al. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. J Clin Oncol. 2015;33(8):944–51.PubMedPubMedCentralGoogle Scholar
  28. Denham JW, Steigler A, Lamb DS, et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011;12(5):451–9.PubMedGoogle Scholar
  29. Denham JW, Joseph D, Lamb DS, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. Lancet Oncol. 2014;15(10):1076–89.PubMedGoogle Scholar
  30. Deutsch I, Zelefsky MJ, Zhang Z, et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy. 2010;9(4):313–8.PubMedGoogle Scholar
  31. Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37.PubMedPubMedCentralGoogle Scholar
  32. Dubray BM, Beckendorf V, Guerif S, et al. Does short-term androgen depletion add to high dose radiotherapy (80 Gy) in localized intermediate risk prostate cancer? Final analysis of the GETUG 14 randomized trial (EU-20503/NCT00104741). J Clin Oncol. 2016;34(15_suppl):5021.Google Scholar
  33. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed: Springer; 2010.Google Scholar
  34. Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol. 2009;27(1):92–9.PubMedGoogle Scholar
  35. Eifler JB, Humphreys EB, Agro M, Partin AW, Trock BJ, Han M. Causes of death after radical prostatectomy at a large tertiary center. J Urol. 2012;188(3):798–802.PubMedGoogle Scholar
  36. Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016a;40(2):244.Google Scholar
  37. Fizazi K, Faivre L, Lesaunier F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol. 2015;16(7):787–94.PubMedGoogle Scholar
  38. Fosså SD, Wiklund F, Klepp O, et al. Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7. Eur Urol. 2016;70(4):684–91.PubMedGoogle Scholar
  39. Fransson P, Lund J-A, Damber J-E, et al. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. The Lancet Oncology. 2009;10(4):370–80. https://doi.org/10.1016/S1470-2045(09)70027-0.PubMedGoogle Scholar
  40. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294(4):433–9.PubMedGoogle Scholar
  41. Grimm P, Billiet I, Bostwick D, et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int. 2012;109(Suppl 1):22–9.PubMedGoogle Scholar
  42. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375(15):1415–24.PubMedGoogle Scholar
  43. Harris VA, Staffurth J, Naismith O, et al. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation Harris therapy. Int J Radiat Oncol Biol Phys. 2015;92(4):874–83.PubMedGoogle Scholar
  44. Hauswald H, Kamrava MR, Fallon JM, et al. High-dose-rate monotherapy for localized prostate cancer: 10-year results. Int J Radiat Oncol Biol Phys. 2016;94(4):667–74.PubMedGoogle Scholar
  45. Hoffman KE, Skinner H, Pugh TJ, et al. Patient-reported urinary, bowel, and sexual function after hypofractionated intensity-modulated radiation therapy for prostate cancer: results from a randomized trial. Am J Clin Oncol. 2016. [Epub ahead of print]Google Scholar
  46. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008;26(15):2497–504.PubMedGoogle Scholar
  47. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012;103(2):217–22.PubMedGoogle Scholar
  48. Hsu I-C, Bae K, Shinohara K, et al. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321. Int J Radiat Oncol Biol Phys. 2010;78(3):751–8.PubMedPubMedCentralGoogle Scholar
  49. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. NEJM. 2017;377(4):338–51.Google Scholar
  50. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163–77.PubMedPubMedCentralGoogle Scholar
  51. Jemal A, Ma J, Siegel R, Fedewa S, Brawley O, Ward EM. Prostate cancer incidence rates 2 years after the US preventive services task force recommendations against screening. August: JAMA Oncol; 2016.PubMedGoogle Scholar
  52. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365(2):107–18.PubMedGoogle Scholar
  53. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology. 2001;58(3):393–9.PubMedGoogle Scholar
  54. Katz SJ. JAMA Surg. 2016 Aug 17; 151(8): e161137.Google Scholar
  55. Khor R, Duchesne G, Tai K-H, et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(3):679–85.PubMedGoogle Scholar
  56. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol. 2013;109(2):217–21.PubMedGoogle Scholar
  57. Kittel JA, Reddy CA, Smith KL, et al. Long-term efficacy and toxicity of low-dose-rate 125I prostate brachytherapy as monotherapy in low-, intermediate-, and high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2015;92(4):884–93.PubMedGoogle Scholar
  58. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):67–74.PubMedGoogle Scholar
  59. Laverdiere J, Nabid A, De Bedoya LD, et al. The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol. 2004;171:1137–40.PubMedGoogle Scholar
  60. Lawton CA, Winter K, Grignon D, et al. Androgen suppression plus radiation versus radiation alone for patients with stage d1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial radiation therapy oncology group 85-31. J Clin Oncol. 2005;23:800–7.PubMedGoogle Scholar
  61. Lawton CA, Michalski J, El-Naqa I, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(2):383–7.PubMedGoogle Scholar
  62. Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34(20):2325–32.PubMedPubMedCentralGoogle Scholar
  63. Lennernäs B, Majumder K, Damber J-E, et al. Radical prostatectomy versus high-dose irradiation in localized/locally advanced prostate cancer: a Swedish multicenter randomized trial with patient-reported outcomes. Acta Oncol. 2015;54(6):875–81.PubMedGoogle Scholar
  64. Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst. 2015;107(7):1–10.Google Scholar
  65. Lukka H, Hayter C, Julian JA, et al. Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. JCO. 2005;23(25):6132–8.Google Scholar
  66. Manoharan M, Bird VG, Kim SS, Civantos F, Soloway MS. Outcome after radical prostatectomy with a pretreatment prostate biopsy Gleason score of ≥8. BJU Int. 2003;92(6):539–44.Google Scholar
  67. Marina O, Gustafson GS, Kestin LL, et al. Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients. Brachytherapy. 2014;13(1):59–67.PubMedGoogle Scholar
  68. Mason MD, Parulekar WR, Sydes MR, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33(19):2143–50.PubMedPubMedCentralGoogle Scholar
  69. Mertan FV, Lindenberg L, Choyke PL, Turkbey B. PET imaging of recurrent and metastatic prostate cancer with novel tracers. Future Oncol. 2016;12(21):2463–77.PubMedPubMedCentralGoogle Scholar
  70. Messing EM, Manola J, Yao J, et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 2006;7(6):472–9.PubMedGoogle Scholar
  71. Michalski JM, Moughan J, Purdy J, et al. A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer. ASCO Meet Abstr. 2015;33(Suppl 7):4.Google Scholar
  72. Morikawa LK, Roach M. Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J Radiat Oncol Biol Phys. 2011;80(1):6–16.PubMedGoogle Scholar
  73. Morris WJ, Tyldesley S, Pai HH, et al. ASCEND-RT: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clinc Oncol. 2015;33(suppl 7; abstr 3).Google Scholar
  74. Nabid A, Carrier N, Andre-Guy M, et al. High-risk prostate cancer treated with pelvic radiotherapy and 36 versus 18 months of androgen blockade: Results of a phase III randomized study. J Clin Oncol. 2013;31(suppl 6; abstr 3).Google Scholar
  75. Nabid A, Carrier N, Vigneault E, et al. A phase III trial of short-term androgen deprivation therapy in intermediate-risk prostate cancer treated with radiotherapy. J Clin Oncol. 2015;33(suppl; abstr 5019).Google Scholar
  76. Nguyen PL, Je Y, Schutz FAB, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66.Google Scholar
  77. Pagliarulo V, Hawes D, Brands FH, et al. Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol. 2006;24(18):2735–42.PubMedGoogle Scholar
  78. Penson DF, McLerran D, Feng Z, et al. 5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol. 2005;173(5):1701–5.PubMedGoogle Scholar
  79. Pieczonka CM, Mariados N, Sylvester JE, et al. Hydrogel spacer application technique, patient tolerance and impact on prostate intensity modulated radiation therapy: results from a prospective, multicenter, Pivotal Randomized Controlled Trial. Urol Pract. 2016;3(2):141–6.Google Scholar
  80. Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C. Assessing contamination and compliance in the prostate component of the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Clin Trials. 2010;7(4):303–11.PubMedGoogle Scholar
  81. Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015;33(4):332–9.PubMedGoogle Scholar
  82. Pollack A, Walker G, Horwitz EM, et al. Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. JCO. 2013;31(31):3860–8.Google Scholar
  83. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25(34):5366–73.PubMedGoogle Scholar
  84. Pommier P, Chabaud S, Lagrange J-L, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Update of the long-term survival results of the GETUG-01 randomized study. Int J Radiat Oncol Biol Phys. 2016;96(4):759–69.PubMedGoogle Scholar
  85. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2008;179(5 Suppl):S20–4.PubMedGoogle Scholar
  86. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(1d7):1591–7.PubMedGoogle Scholar
  87. Prestidge BR, Winter K, Sanda MG, et al. Initial report of NRG oncology/RTOG 0232: a phase 3 study comparing combined external beam radiation and transperineal interstitial permanent brachytherapy with brachytherapy alone for selected patients with intermediate-risk prostatic carcinoma. IJROBP. 2016;96(2):S4.Google Scholar
  88. Ramey SJ, Abramowitz MC, Moghanaki D, et al. Benefit of elective nodal irradiation and androgen deprivation therapy with post prostatectomy salvage radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2016;96(2):S102.Google Scholar
  89. Roach M III. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol. 2008;26(22):3816–7. author reply 3817-3818PubMedGoogle Scholar
  90. Roach M. Should treatment with radiation and androgen deprivation therapy be considered the “gold standard” for men with unfavourable intermediate- to high-risk and locally advanced prostate cancer? Clin Oncol (R Coll Radiol). 2016;28(8):475–8.Google Scholar
  91. Roach M, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585–91. https://doi.org/10.1200/JCO.2007.13.9881.PubMedGoogle Scholar
  92. Roach M, Ceron Lizarraga TL, Lazar AA. Radical prostatectomy versus radiation and androgen deprivation therapy for clinically localized prostate cancer: how good is the evidence? Int J Radiat Oncol Biol Phys. 2015;93(5):1064–70. https://doi.org/10.1016/j.ijrobp.2015.08.005.Google Scholar
  93. Roach M, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation Therapy Oncology Group 9413. JCO. 2003;21(10):1904–11. https://doi.org/10.1200/JCO.2003.05.004.PubMedGoogle Scholar
  94. Roach M, Thomas K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States preventative task force report on screening? J Natl Cancer Inst Monogr. 2012;2012(45):221–9.PubMedPubMedCentralGoogle Scholar
  95. Rodda SL, Tyldesley S, Keyes M, et al. Low-dose-rate prostate brachytherapy is superior to dose-escalated EBRT for unfavorable risk prostate cancer: the results of the ASCENDE-RT randomized control trial. Int J Radiat Oncol Biol Phys. 2015;93(3):E191–2.Google Scholar
  96. Rosenthal SA, Hunt D, Sartor AO, et al. A phase 3 trial of 2 years of androgen suppression and radiation therapy with or without adjuvant chemotherapy for high-risk prostate cancer: final results of Radiation Therapy Oncology Group phase 3 randomized trial NRG oncology RTOG 9902. Int J Radiat Oncol Biol Phys. 2015;93(2):294–302.PubMedPubMedCentralGoogle Scholar
  97. Rusthoven CG, Carlson JA, Waxweiler TV, et al. The impact of definitive local therapy for lymph node-positive prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2014;88(5):1064–73.PubMedGoogle Scholar
  98. Rusthoven CG, Jones BL, Flaig TW, et al. Improved survival with prostate radiation in addition to androgen deprivation therapy for men with newly diagnosed metastatic prostate cancer. J Clin Oncol. 2016;34(24):2835–42.PubMedGoogle Scholar
  99. Sandler H, Chen H, Seth A, et al. A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). J Clin Oncol. 2015;33(18_suppl); abstr LBA5002.Google Scholar
  100. Sathya JR, Davis IR, Julian JA, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol. 2005;23:1192–9.PubMedGoogle Scholar
  101. Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare analysis. J Urol. 2015 Aug;194(2):378–85.PubMedPubMedCentralGoogle Scholar
  102. Scher HI, Lu D, Schreiber NA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. June: JAMA Oncol; 2016.Google Scholar
  103. Schiffner DC, Gottschalk AR, Lometti M, et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67(2):610–9.PubMedGoogle Scholar
  104. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–35.PubMedPubMedCentralGoogle Scholar
  105. Shih HA, Harisinghani M, Zietman AL, et al. Mapping of nodal disease in locally advanced prostate cancer: rethinking the clinical target volume for pelvic nodal irradiation based on vascular rather than bony anatomy. Int J Radiat Oncol Biol Phys. 2005;63:1262–9.PubMedGoogle Scholar
  106. Shipley WU, Seiferheld W, Lukka H, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. NEJM. 2017;376(5):417–28.PubMedGoogle Scholar
  107. Shoag JE, Mittal S, Hu JC. Reevaluating PSA testing rates in the PLCO trial. N Engl J Med. 2016;374(18):1795–6.PubMedGoogle Scholar
  108. Sidhom MA, et al. Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. Radiother Oncol. 2008;88(1):10–9.PubMedGoogle Scholar
  109. Stone NN, Stock RG. 15-year cause specific and all-cause survival following brachytherapy for prostate cancer: negative impact of long-term hormonal therapy. J Urol. 2014;192(3):754–9.PubMedGoogle Scholar
  110. Sweeney CJ, Chen Y-H, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.PubMedPubMedCentralGoogle Scholar
  111. Taylor A, Rockall AG, Rezneck RH, Powell ME. Mapping pelvic lymph nodes: guidelines for delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:1604–12.PubMedGoogle Scholar
  112. Tendulkar RD, Agrawal S, Gao T, et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. 2016;34(30):JCO679647.Google Scholar
  113. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow up of a randomized clinical trial. J Urol. 2009;181(3):956–62.PubMedPubMedCentralGoogle Scholar
  114. Tollefson MK, Leibovich BC, Slezak JM, Zincke H, Blute ML. Long-term prognostic significance of primary Gleason pattern in patients with Gleason score 7 prostate cancer: impact on prostate cancer specific survival. J Urol. 2006;175(2):547–51.PubMedGoogle Scholar
  115. Tward JD, Kokeny KE, Shrieve DC. Radiation therapy for clinically node-positive prostate adenocarcinoma is correlated with improved overall and prostate cancer-specific survival. Pract Radiat Oncol. 2013;3(3):234–40.PubMedGoogle Scholar
  116. Valicenti RK, Thompson I, Albertsen P, et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys. 2013;86(5):822–8.PubMedGoogle Scholar
  117. Van der Kwast TH, Bolla M, Van Poppel H, et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol. 2007;25(27):4178–86.PubMedGoogle Scholar
  118. Vargas CE, Hartsell WF, Dunn M, et al. Hypofractionated versus standard fractionated proton-beam therapy for low-risk prostate cancer: interim results of a randomized trial PCG GU 002. Am J Clin Oncol. 2015;1:1–6.Google Scholar
  119. Wallis CJD, Saskin R, Choo R, et al. Surgery versus radiotherapy for clinically-localized prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(1):21–30.PubMedGoogle Scholar
  120. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004–2013). July: Prostate Cancer Prostatic Dis; 2016.Google Scholar
  121. Widmark A, Gunnlaugsson A, Beckman L, et al. Extreme hypofractionation vs. conventionally fractionated radiotherapy for intermediate risk prostate cancer: early toxicity results from the scandinavian randomized phase III trial “HYPO-RT-PC.” ASTRO Meet Abstr. 2016. Late-breaking abstract 5.Google Scholar
  122. Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–50.PubMedGoogle Scholar
  123. Wong AT, Schwartz D, Osborn V, Safdieh J, Weiner J, Schreiber D. Adjuvant radiation with hormonal therapy is associated with improved survival in men with pathologically involved lymph nodes after radical surgery for prostate cancer. July: Urol Oncol; 2016.Google Scholar
  124. Yoshioka Y, Suzuki O, Isohashi F, et al. High-dose-rate brachytherapy as monotherapy for intermediate- and high-risk prostate cancer: clinical results for a median 8-year follow-up. Int J Radiat Oncol Biol Phys. 2016;94(4):675–82.PubMedGoogle Scholar
  125. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001;58:233–9.PubMedGoogle Scholar
  126. Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(3):320–7.PubMedGoogle Scholar
  127. Zelefsky MJ, Yamada Y, Cohen GN, et al. Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007a;67(1):65–70.PubMedGoogle Scholar
  128. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007b;67(2):327–33.PubMedGoogle Scholar
  129. Zhao SG, Chang SL, Spratt DE, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016;17(11):1612–20.PubMedGoogle Scholar
  130. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol. 2010;28(7):1106–11.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Michael A. Garcia
    • 1
  • Eric K. Hansen
    • 2
  • Mack RoachIII
    • 1
  1. 1.Department of Radiation Oncology, University of California San FranciscoSan FranciscoUSA
  2. 2.The Oregon Clinic, Radiation Oncology, Providence St. Vincent Medical CenterPortlandUSA

Personalised recommendations